REDHILL B.S.ADR 10/IL-,01 Forum: Community User: MeisterYoda1

Wenn du den PDUFA-Run (Sicherheitsvariante) mitmachen willst, ist es zu spät. Wenn du auf den Kurs nach hoffentlich positiven PDUFA- Entscheid (Risikovariante) wetten willst, ist es gerade noch rechtzeitig. Wir haben jetzt den Kurs erreicht den Cosmo vor 1 Woche für eine Aktie gezahlt hat.

Hola Geselle mich Mal zur späten Stunde dazu😉 lohnt der Einstieg noch was sagt ihr?

Heute nachbörslich oder Montag. Talicia soll dann direkt im Anschluss vermarktet werden. 8 Jahre Marktmonopol🤑🤑 was das für den Kurs bedeuten könnte

😂 der poors ist echt eine *** Wann rechnest du hier mit einer Meldung ? Ich denke mal Montag

Dann muss ich mehr 🍺 hinstellen: 🍺🍺🍺🍺🍺🍺🍺🍺🍺🍺🍺 Und einen Enzian dazu

Da brauchen wir noch da moz 😂🍺🍺

Jetzt nicht mehr🍾🍻 Willkommen in meinem Thread. Nimm Platz und trink etwas: 🍷🍷🍷🍷🍷🍸🍸🍸🍸🍸🍹🍹🍹🍹🍹🍺🍺🍺🍺🍺🥃🥃🥃🥃🥃

Hallo Schorsch, bist ja ganz alleine hier

RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting ...RHB-1051 (Talicia®, H. pylori infection) and RHB-104 (Crohn’s disease) will be presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting, being held October 25-30, in San Antonio, Texas. In addition to the four presentations at ACG, RedHill will be sponsoring an H. pylori Disease State educational presentation in the Exhibitor Theater and will have a booth (#426) located in the Exhibit Hall. http://www.globenewswire.com/news-release/2019/10/28/1936363/0/en/RedHill-Biopharma-to-Present-New-Phase-3-Data-on-RHB-105-and-RHB-104-at-the-American-College-of-Gastroenterology-2019-Annual-Meeting.html

New analyst Rating: https://www.edisongroup.com/publication/cosmo-deal-new-asset-stronger-balance-sheet/25347/

COSMO Pharmaceuticals N.V.: Cosmo lizensiert Aemcolo für USA an RedHill Biopharma und beteiligt sich mit 19.56% am Unternehmen Cosmo lizensiert Aemcolofür USA an RedHill Biopharma und beteiligt sich mit 19.56% am Unternehmen https://www.finanznachrichten.de/nachrichten-2019-10/47938453-cosmo-pharmaceuticals-n-v-cosmo-lizensiert-aemcolo-fuer-usa-an-redhill-biopharma-und-beteiligt-sich-mit-19-56-am-unternehmen-353.htm

RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-*** Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease https://finance.yahoo.com/news/redhill-biopharma-announces-full-results-130000151.html?.tsrc=rss&guccounter=1

RedHill Biopharma Provides H2/2019 R&D Update https://www.globenewswire.com/news-release/2019/09/26/1921232/0/en/RedHill-Biopharma-Provides-H2-2019-R-D-Update.html

RedHill And Talicia In H. Pylori: The PDUFA Countdown TRENDING PORTFOLIO PEOPLE MARKET NEWS STOCK IDEAS DIVIDENDS INVESTING STRATEGY REITS WALL STREET BREAKFAST ON THE MOVE DIVIDEND NEWS MARKET OUTLOOK  First Genesis Consulting Follow Long Ideas Healthcare  Israel RedHill And Talicia In H. Pylori: The PDUFA Countdown Aug. 7, 2019 8:17 PM ETRedHill Biopharma Ltd.(RDHL)2 Comments Summary The multi-year laborious clinical trials to demonstrate therapeutic efficacy for Talicia in H. pylori eradication were validated with positive clinical outcomes in two Phase 3 trials. The NDA for Talicia, as first-*** eradication treatment for H. pylori infection, was submitted in Q2/2019. I presume RedHill’s thanksgiving clinical desire has to be a favorable Adcom review that leads to NDA approval by the FDA for Talicia. I concur. The launch of Talicia in the United States is expected to begin in Q4/2019 pending a successful PDUFA outcome. This idea was discussed in more depth with members of my private investing community, Liver Therapy Forum (LTF). https://seekingalpha.com/article/4282928-redhill-talicia-h-pylori-pdufa-countdown?source=quotemedia_readmore

Back YahooFINANCE RedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019 GlobeNewswireJuly 15, 2019, 1:00 PM GMT+2 TEL-AVIV, Israel and RALEIGH, N.C., July 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it will report its second quarter 2019 financial results and operational highlights on Tuesday, July 23, 2019. The Company will host a conference call on Tuesday, July 23, 2019 at 8:30 a.m. EDT to review the second quarter 2019 financial results and operational highlights.

RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia® U.S. FDA accepts NDA for priority review   PDUFA date set for November 2, 2019   H. pylori infection affects approximately 35% of the U.S. population and is the strongest risk factor for the development of gastric cancer and a major risk factor for peptic ulcer disease and MALT lymphoma Commercial launch of Talicia with RedHill’s existing U.S. sales force is planned shortly following potential FDAapproval. If approved, Talicia would be eligible for a total of eight years of U.S. market exclusivity. https://ir.redhillbio.com/news-releases/news-release-details/redhill-biopharma-announces-fda-acceptance-new-drug-application